Conformational adaptation of nuclear receptor ligand binding domains to agonists: Potential for novel approaches to ligand design

Marie Togashi, Sabine Borngraeber, Ben Sandler, Robert J. Fletterick, Paul Webb, John D. Baxter

Research output: Contribution to journalArticlepeer-review

39 Scopus citations

Abstract

Ligands occupy the core of nuclear receptor (NR) ligand binding domains (LBDs) and modulate NR function. X-ray structures of NR LBDs reveal most NR agonists fill the enclosed pocket and promote packing of C-terminal helix 12 (H12), whereas the pockets of unliganded NR LBDs differ. Here, we review evidence that NR pockets rearrange to accommodate different agonists. Some thyroid hormone receptor (TR) ligands with 5′ extensions designed to perturb H12 act as antagonists, but many are agonists. One mode of adaptation is seen in a TR/thyroxine complex; the pocket expands to accommodate a 5′ iodine extension. Crystals of other NR LBDs reveal that the pocket can expand or contract and some agonists do not fill the pocket. A TRβ structure in complex with an isoform selective drug (GC-24) reveals another mode of adaptation; the LBD hydrophobic interior opens to accommodate a bulky 3′ benzyl extension. We suggest that placement of extensions on NR agonists will highlight unexpected areas of flexibility within LBDs that could accommodate extensions; thereby enhancing the selectivity of agonist binding to particular NRs. Finally, agonists that induce similar LBD structures differ in their activities and we discuss strategies to reveal subtle structural differences responsible for these effects.

Original languageEnglish (US)
Pages (from-to)127-137
Number of pages11
JournalJournal of Steroid Biochemistry and Molecular Biology
Volume93
Issue number2-5
DOIs
StatePublished - Feb 2005

Keywords

  • Thyroid hormone
  • Thyroid hormone receptor

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Fingerprint Dive into the research topics of 'Conformational adaptation of nuclear receptor ligand binding domains to agonists: Potential for novel approaches to ligand design'. Together they form a unique fingerprint.

Cite this